Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDEI9X)

Drug Name
ISIS 104254 Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
TTD Drug ID
DMDEI9X

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting RIP2 messenger RNA (RIP2 mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ISIS-CRP DMQDUG4 Cardiovascular disease BA00-BE2Z Phase 1 [2]
NM-PP1 DMS8H5Q Discovery agent N.A. Investigative [2]
ISIS 104258 DMUC3L0 Discovery agent N.A. Investigative [1]
ISIS 104211 DMPKQ61 Discovery agent N.A. Investigative [1]
ISIS 104257 DMSDCGV Discovery agent N.A. Investigative [1]
ISIS 104256 DMHUX9A Discovery agent N.A. Investigative [1]
ISIS 104255 DMAI5B8 Discovery agent N.A. Investigative [1]
ISIS 104253 DMME8JP Discovery agent N.A. Investigative [1]
Src kinase inhibitor I DMUZP9V Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
RIP2 messenger RNA (RIP2 mRNA) TTCQ2E5 RIPK2_HUMAN Not Available [1]

References

1 US patent application no. 6,426,221, Antisense modulation of RIP2 expression.
2 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.